Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Harrington, Bonnie K., Gardner, Heather L., Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R., Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C., Russell, Duncan S., Zhang, Xiaoli, Urie, Bridget K., London, Cheryl A., Byrd, John C., Johnson, Amy J., Kisseberth, William C.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4951150/
https://ncbi.nlm.nih.gov/pubmed/27434128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0159607
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados